BTIG Initiates Coverage On Serina Therapeutics with Buy Rating, Announces Price Target of $8
BTIG analyst Thomas Shrader initiates coverage on Serina Therapeutics (AMEX: SER ) with a Buy rating and announces Price Target of $8.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.